Market Place
Sourcing Support
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
11 Jan 2023 //
BUSINESSWIRE
Imago doses first subject in Phase II myelofibrosis treatment trial
22 Dec 2022 //
CLINICALTRIALSARENA
Imago Announces First Participant Dosed Ph 2 Study of Bomedemstat
20 Dec 2022 //
GLOBENEWSWIRE
Merck begins Tender Offer to acquire Imago BioSciences
12 Dec 2022 //
INDIANPHARMAPOST
Imago BioSciences Presents Positive Data from Ongoing Ph2 Study of Bomedemstat
12 Dec 2022 //
GLOBENEWSWIRE
Imago BioSciences Presents Positive Data from Ongoing Ph2 Study of Bomedemstat
12 Dec 2022 //
GLOBENEWSWIRE
Imago Announces 1st Participant Dosed Ph1 Study of Bomedemstat Combo Venetoclax
30 Nov 2022 //
GLOBENEWSWIRE
Merck bulks up in haematology, buying Imago for $1.35bn
22 Nov 2022 //
PRESS RELEASE
Imago BioSciences Reports Third Quarter 2022 Financial Results
09 Nov 2022 //
PRESS RELEASE
Imago BioSciences to Participate in Upcoming Investor Conferences
07 Nov 2022 //
GLOBENEWSWIRE
Imago BioSciences Announces Oral Data Presentations at Meeting
03 Nov 2022 //
PRESS RELEASE
Imago BioSciences (NASDAQ:IMGO) Price Target Lowered to $35.00 at HC Wainwright
17 Aug 2022 //
DEFENSEWORLD
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides
12 Aug 2022 //
GLOBENEWSWIRE
Imago Bio to Participate in the 2022 Wedbush PacGrow Healthcare Conference
03 Aug 2022 //
GLOBENEWSWIRE
Imago Presents +ve Data from Ongoing PII Study in Essential Thrombocythemia
09 Jun 2022 //
GLOBENEWSWIRE
Imago Presents +ve Data from PII Study of Bomedemstat in Advanced Myelofibrosis
09 Jun 2022 //
GLOBENEWSWIRE
Imago BioSciences to Host Virtual Investor Event
06 Jun 2022 //
GLOBENEWSWIRE
Imago BioSciences to Participate in Upcoming Investor Conferences
16 May 2022 //
GLOBENEWSWIRE
Imago BioSciences Announces Upcoming Presentations on PII Studies of Bomedemstat
12 May 2022 //
GLOBENEWSWIRE
Imago BioSciences Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Imago Begins Dosing in Investigator-Sponsored Study of Bomedemstat+Atezolizumab
09 May 2022 //
GLOBENEWSWIRE
Imago BioSciences Announces Completion of Enrollment in PII Study of Bomedemstat
03 May 2022 //
GLOBENEWSWIRE
Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Imago BioSciences Appoints Michael Arenberg to COO
23 Mar 2022 //
PRESS RELEASE
Imago Bio Appoints Michael Arenberg to Chief Operating and Business Officer
23 Mar 2022 //
GLOBENEWSWIRE
Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference
28 Feb 2022 //
GLOBENEWSWIRE
Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022
04 Feb 2022 //
GLOBENEWSWIRE
Imago Bio Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat
12 Dec 2021 //
BUSINESSWIRE
Imago Bio Presents Positive Data of Bomedemstat in Advanced Myelofibrosis
11 Dec 2021 //
PRESS RELEASE
Imago BioSciences to Host Virtual Investor Event
01 Dec 2021 //
PRESS RELEASE
Imago BioSciences Appoints Laurie Keating to Board of Directors
18 Nov 2021 //
PRESS RELEASE
Imago BioSciences Announces Oral Data Presentations at the UpcomingASH
04 Nov 2021 //
BUSINESSWIRE
Imago BioSciences Reports Second Quarter 2021 Financial Results
19 Aug 2021 //
BUSINESSWIRE
Imago BioSciences Receives Orphan Designation From EMA for Bomedemstat
30 Jul 2021 //
BUSINESS WIRE
Imago BioSciences, Inc. Announces Exercise of Underwriters’ Option
26 Jul 2021 //
BUSINESSWIRE
Imago BioSciences Announces Closing of $134.4M Initial Public Offering
20 Jul 2021 //
BUSINESSWIRE
Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering
16 Jul 2021 //
BUSINESS WIRE
Kriya raises $100m in Series B funding round to develop gene therapies
15 Jul 2021 //
BIOSPACE
Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering
15 Jul 2021 //
BUSINESS WIRE
Imago BioSciences, Inc. Announces Proposed Initial Public Offering
12 Jul 2021 //
BUSINESSWIRE
Imago eyes $105M IPO to fuel blood cancer programs
12 Jul 2021 //
FIERCEBIOTECH
Bone marrow disease biotech Imago BioSciences files for a $100 million IPO
25 Jun 2021 //
RENAISSANCECAPITAL
Imago’s Bomedemstat shows Encouraging Clinical Activity in Phase 2 Data
11 Jun 2021 //
BUSINESSWIRE
Imago’s Bomedemstat shows Encouraging Clinical Activity in Phase 2 Data
11 Jun 2021 //
BUSINESSWIRE
Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat
21 May 2021 //
BUSINESSWIRE
Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat
21 May 2021 //
BUSINESSWIRE
Imago BioSciences Expands Ph 2 Trial of Bomedemstat (IMG-7289)
30 Nov 2020 //
BUSINESSWIRE
Imago BioSciences to Participate in the Piper Sandler 32nd Annual Healthcare
23 Nov 2020 //
BUSINESSWIRE
Imago Biosciences caps off an $80M Series C with an IPO promise for 2021
20 Nov 2020 //
ENDPTS
Interim Data From Imago BioSciences’ Phase 2b Study of Bomedemstat (IMG-7289)
05 Nov 2020 //
BUSINESSWIRE
Imago BioSciences Doses First Patient in Ph 2b Study of Bomedemstat (IMG-7289)
01 Oct 2020 //
BUSINESSWIRE
Imago Doses First Patient in Ph2b Study of Bomedemstat (IMG-7289)
01 Oct 2020 //
BUSINESSWIRE
Imago Granted Access by European Medicines Agency to PRIME Scheme for IMG-7289
31 Jul 2020 //
BIOSPACE
Imago Granted Access by European Medicines Agency to PRIME Scheme for IMG-7289
30 Jul 2020 //
BUSINESSWIRE
Imago Granted Access by European Medicines Agency to PRIME Scheme for IMG-7289
30 Jul 2020 //
BUSINESSWIRE
